Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berodual Respimat vs MDI in COPD
NCT02173782Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 1998
- Primary completion
- Apr 1999
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of fenoterol and ipratropium bromide in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Average forced expiratory volume in one second between 0 and 1 hour at 12 weeks. Started Feb 1998; status: completed.
02
Drugs
fenoterolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02173782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173782.